AREVA Med LLC

Orano Med seeks to develop a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), a rare alpha-emitting radioisotope and one of the most potent therapeutic payloads against cancer cells. Although oncology research has made tremendous progress in recent years, medical needs remain unmet for many types of cancer. Our approach, known as Targeted Alpha Therapy (TAT), opens up promising prospects for patients not responding to existing treatments. Orano Med masters 212Pb chemistry and conjugation technology (including proprietary antibody site specific conjugation via its subsidiary Macrocyclics acquired in 2011) and is able to radiolabel 212Pb to various biological vectors (peptides, antibodies, etc.) targeting antigens or receptors expressed in a wide range of cancers. We focus our developments on areas of high unmet needs where 212Pb-labeled compounds could make a difference and, since 2016, we have been equipped with a preclinical facility to accelerate the transition of our molecules into clinical research.